Why is Medicamen Biotec falling/rising?

As of 09-Jul, Medicamen Biotech Ltd's stock price is currently at Rs 393.95, reflecting a decrease of Rs 8.2 or 2.04%. The stock has been underperforming, having fallen consecutively for the last two days, with a total decline of 2.18% during this period. It is also trading close to its 52-week low, just 4.3% above the low of Rs 377. The stock has shown significant underperformance against the benchmark, with a 1-week return of -2.25% compared to the Sensex's slight gain of 0.15%. Additionally, the company has reported a low return on capital employed (ROCE) of 2.8 and a declining operating profit over the last five years, which has contributed to its negative sentiment among investors.
Broader market context indicates that Medicamen Biotech has consistently underperformed against the benchmark indices over the past three years, with a year-to-date return of -22.64% compared to the Sensex's gain of 6.91%. The stock's liquidity is also a concern, as evidenced by a significant drop in delivery volume, which has decreased by 22.56% against the five-day average. This lack of investor participation, combined with poor financial metrics such as the lowest net sales and cash equivalents, suggests a challenging environment for the company, further driving down investor confidence and contributing to the stock's decline.